Latest Targeted therapy Stories
At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs).
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
Pathway Analysis Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 3, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused
Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and
Combined Gene and Protein Analysis of Sarcoma Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 2, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading
Large International Cohort of 17 GI Cancer Types Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 1, 2014 /PRNewswire/ -- Caris Life Sciences, a leading
Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc.
- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO,
Tozaride Targeted Therapy Shows Tumor Reduction in Animal Model Somerville, Massachusetts (PRWEB) May 28, 2014 Andarix Pharmaceuticals, a clinical stage
Strategic dealmaker to advance Epic's leading circulating tumor cell (CTC) technology as a rapid and non-invasive platform for on-label, marketed companion diagnostics SAN DIEGO, May